177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases

Bone is the most common metastatic site in patients with prostate cancer. Lu-177-DOTA-ibandronic acid (Lu-177-DOTA-IBA) is a new therapeutic radiopharmaceutical targeting bone metastasis. We report a case of refractory bone pain due to bone metastasis, who demonstrated an excellent therapy response after 3 cycles of Lu-177-DOTA-IBA therapy. In addition, the patient did not have any observable adverse reactions. Lu-177-DOTA-IBA may be a promising radiopharmaceutical for the treatment of bone metastasis.

Automated summary

Bone metastasis is common in prostate cancer patients, and Lu-177-DOTA-ibandronic acid (Lu-177-DOTA-IBA) is a promising therapeutic radiopharmaceutical for its treatment. We present a case of refractory bone pain due to bone metastasis, which showed an excellent response to 3 cycles of Lu-177-DOTA-IBA therapy. The patient did not experience any observable adverse reactions.